by OncoAdmin | Jun 20, 2022 | Press Releases Eng
PRESS RELEASE Börje Haraldsson appointed CEO of Oncorena AB LUND, SWEDEN, June 20, 2022 – Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer, announces that the Board of Directors of...
by OncoAdmin | May 23, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Presents Two Abstracts on Orellanine at the Nordic Society of Nephrology LUND, SWEDEN, May 23, 2022 – Oncorena presented two abstracts on orellanine at the Nordic Society of Nephrology, in Odense, Denmark on May 4-7. Oncorena is developing...
by OncoAdmin | Feb 2, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Strengthens its Management Team and Appoints Professor Börje Haraldsson as Chief Scientific Officer LUND, SWEDEN, February 2, 2022 – Oncorena, developing a potential breakthrough therapy for advanced renal cancer, announced today that...
by OncoAdmin | Feb 1, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska University Hospital in Sweden LUND, SWEDEN, February 1, 2022 – Oncorena today announced the initiation of the Phase I-II clinical...
by OncoAdmin | Dec 23, 2021 | Press Releases Eng
PRESS RELEASE Oncorena Secures Financing of the Company’s Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer LUND, SWEDEN, December 23, 2021 – Oncorena, developing a potential breakthrough therapy for advanced renal...
by OncoAdmin | Mar 1, 2021 | Press Releases Eng
PRESS RELEASE Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients LUND, SWEDEN, March 1, 2021 – Oncorena, dedicated to developing a unique and potential breakthrough therapy...
